Lisdexamfetamine

# Research Output: Lisdexamfetamine

## Chemical Identity

**Verified against PubChem CID 11597698 [Ref 1]:**

| Property | Value |
|---|---|
| PubChem CID | 11597698 (free base); 11597697 (dimesylate salt) |
| IUPAC name | (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide |
| Molecular formula | C₁₅H₂₅N₃O |
| Molecular weight | 263.38 g/mol (free base) |
| InChIKey | VOBHXZCDAVEXEY-JSGCOSHPSA-N |
| Isomeric SMILES | C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN |
| CAS number | 608137-33-3 (dimesylate salt) |

**Discrepancies with seed data:** The seed data listed blank SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID. All five fields are now populated from PubChem and verified web sources [Ref 1, Ref 36].

**Structural notes:** Lisdexamfetamine (LDX) is a prodrug consisting of d-amphetamine (dextroamphetamine) covalently bound via an amide bond to the naturally occurring amino acid L-lysine [Ref 4]. Both chiral centres are designated (S) configuration. The drug itself is pharmacologically inactive until the lysine moiety is cleaved, releasing the active d-amphetamine. The dimesylate salt form (MW 455.49 g/mol) is used pharmaceutically.

---

## Pharmacology

### Mechanism of Action

LDX is itself pharmacologically inactive. Following oral administration, LDX is cleaved by enzymatic hydrolysis in the bloodstream — specifically in red blood cells (RBCs) — to release d-amphetamine (the active moiety) and L-lysine [Ref 4, Ref 40].

**d-Amphetamine acts through three converging mechanisms [Ref 2, Ref 3, Ref 40]:**

1. **Monoamine transporter reversal (carrier-mediated release):** d-Amphetamine enters presynaptic neurons via the dopamine transporter (DAT) and norepinephrine transporter (NAT/NET). Inside the neuron, it drives reversal of these transporters, causing non-exocytotic efflux of dopamine (DA) and norepinephrine (NE) into the synapse [Ref 3, Ref 40].

2. **Vesicular monoamine transporter 2 (VMAT2) disruption:** d-Amphetamine disrupts VMAT2 function, depleting monoamine storage vesicles and increasing the cytoplasmic pool of DA/NE available for transporter-mediated release [Ref 2, Ref 40].

3. **Reuptake inhibition:** d-Amphetamine competitively inhibits DAT and NET, slowing the clearance of released DA/NE from the synapse [Ref 2].

The net effect is a large, sustained increase in synaptic DA (most prominently in striatum and prefrontal cortex) and NE (most prominently in prefrontal cortex), which is considered the primary basis of both therapeutic efficacy in ADHD and the drug's stimulant and potential abuse effects [Ref 3, Ref 40].

**Serotonin release:** d-Amphetamine also promotes serotonin (5-HT) release via SERT, though with substantially lower potency than DA/NE release. This serotonergic activity is weaker than that of MDMA but is pharmacologically significant and contributes to both subjective effects and drug interaction risks [Ref 3].

**TAAR1 agonism:** d-Amphetamine is an agonist at the trace amine-associated receptor 1 (TAAR1), which modulates dopaminergic, serotonergic, and glutamatergic neurotransmission. TAAR1 activation may contribute to additional regulatory effects on monoamine release [Ref 34].

**Binding affinities:** Specific Ki/EC50 data for LDX (the prodrug) are not published, because LDX itself is pharmacologically inert. d-Amphetamine's binding affinities at DAT, NET, and SERT are well characterised in the literature, but substrate-based release assays (not simple binding affinities) best capture its mechanism. No LDX-specific binding affinity studies were identified through API searches.

### Pharmacokinetics

Data from human PK studies [Ref 5, Ref 13, Ref 29, Ref 35]:

| Parameter | Lisdexamfetamine (prodrug) | d-Amphetamine (active metabolite) |
|---|---|---|
| Tmax | 1.0–2.1 h | 3.0–4.7 h |
| Elimination t½ | 0.4–0.9 h | 8.6–15.0 h |
| Food effect on Tmax | Delayed ~1 h | Delayed ~1 h |
| Food effect on AUC | No significant change | No significant change |

**Absorption:** LDX is absorbed from the small intestine (not colon) via the high-capacity peptide transporter PEPT1, a carrier-mediated process analogous to the absorption of di- and tri-peptides [Ref 4]. LDX portal blood levels are approximately 10-fold higher than systemic levels, suggesting significant first-pass extraction.

**Conversion to d-amphetamine:** Hydrolytic cleavage occurs primarily in RBCs via an unidentified high-capacity enzymatic system — not in the liver or kidney. This RBC-mediated hydrolysis contributes to the consistent, reproducible PK profile of LDX compared to other long-acting stimulant formulations. The rate-limited nature of this conversion produces a lower Cmax and extended Tmax for d-amphetamine compared to equivalent doses of immediate-release d-amphetamine [Ref 4, Ref 29, Ref 30].

**Food effect:** Food delays the Tmax of both LDX and d-amphetamine by approximately 1 hour but does not significantly affect d-amphetamine AUC or Cmax. LDX can be administered with or without food [Ref 5].

**Duration of clinical effect:** Therapeutic effects persist for at least 13 hours post-dose in children and at least 14 hours post-dose in adults — longer than any other published long-acting amphetamine formulation [Ref 29].

**Intranasal vs. oral PK:** A crossover study demonstrated that intranasal LDX does not substantially increase d-amphetamine Cmax compared to oral administration, consistent with the PEPT1-mediated absorption model and supporting the formulation's abuse-deterrent rationale [Ref 14].

**IV abuse PK:** Following IV administration of LDX 50 mg, d-amphetamine Cmax was 38.9 ng/mL (Tmax 2.51 h), compared to 105 ng/mL (Tmax 0.82 h) after IV d-amphetamine 20 mg — demonstrating that the prodrug structure substantially blunts the rate of rise even via parenteral routes [Ref 6].

**Urinary excretion:** d-Amphetamine is excreted renally. Urinary pH significantly affects elimination: alkaline urine (e.g., bicarbonate co-administration) reduces excretion and prolongs effects; acidic urine (e.g., ascorbic acid, ammonium chloride) increases excretion and reduces duration. This is a known interaction class effect for all amphetamines (noted in FDA prescribing information [Ref 35]).

---

## History

### Discovery and Development

Lisdexamfetamine was developed by New River Pharmaceuticals Inc. (Blacksburg, Virginia, USA), a biopharmaceutical company founded with the express aim of creating abuse-deterrent stimulant prodrugs. The drug was originally designated NRP104. The key design principle was to covalently conjugate d-amphetamine to L-lysine, exploiting the high-capacity PEPT1 intestinal transporter to ensure reliable oral bioavailability while creating a rate-limiting enzymatic barrier (RBC hydrolysis) that could not be bypassed by crushing, snorting, or injecting the drug [Ref 15, Ref 19].

### Regulatory Timeline

- **February 23, 2007:** FDA approved LDX (Vyvanse®) for ADHD in children aged 6–12 years, making it the first Schedule II stimulant prodrug approved in the US [Ref 19, Ref 20].
- **February 2007:** Shire Pharmaceuticals announced an agreement to acquire New River Pharmaceuticals for approximately $2.6 billion USD.
- **2008:** FDA label expanded to cover adult ADHD.
- **January 30, 2015:** FDA approved LDX (Vyvanse®) for moderate-to-severe binge eating disorder (BED) in adults — the first and, as of 2026, still the only FDA-approved pharmacotherapy for BED [Ref 9, Ref 18, Ref 39].
- **2012–2015:** European approvals under the brand name Elvanse® in multiple countries (UK, Germany, Spain, Denmark, Sweden, Norway, Finland).
- **2015:** EU decentralised procedure positive opinion for Elvanse Adult® for adult ADHD [Ref 21].
- **March 2019:** Approved in Japan (Vyvanse®) for pediatric ADHD [Ref 2].
- **2023:** First generic versions approved by FDA following patent expiry [Ref 20].

### Development Context

LDX was explicitly developed as an abuse-deterrent reformulation of d-amphetamine. The pivotal human IV abuse liability study (Jasinski & Krishnan 2009 [Ref 6]) was integral to the regulatory submission, demonstrating that IV LDX produced significantly lower euphoria/liking than IV d-amphetamine despite delivering similar total d-amphetamine exposure over time.

---

## Subjective Effects

### Published Descriptions

**From controlled clinical trials in adults (ADHD populations):**
LDX produces increased alertness, enhanced focus and attention, reduced impulsivity, and improved executive function and working memory. Clinical studies document improvements on ADHD rating scales (ADHD-RS-IV, CAARS) and executive function measures across pediatric and adult populations [Ref 7, Ref 24, Ref 27].

**From BED trial (Schneider et al. 2022, n=22 women) [Ref 25]:**
An acute 50 mg dose of LDX produced: reduced self-reported appetite, reduced food intake (meals and snack), enhanced sustained attention and reduced impulsive responding (continuous performance task), reduced thalamic activation during food cues (fMRI), reduced eating rate. No significant effect on working memory or emotional bias was observed.

**From IV abuse liability study (Jasinski & Krishnan 2009) [Ref 6]:**
IV LDX 50 mg produced significantly lower drug-liking scores vs. placebo (p NS), while IV d-amphetamine 20 mg produced significantly elevated liking (p < 0.05). The blunted subjective response corresponds to the slower Cmax rise of d-amphetamine from LDX.

**Common adverse effects from clinical trials across populations [Ref 9, Ref 11, Ref 18, Ref 28]:**
- Decreased appetite / anorexia (most common in pediatric trials)
- Insomnia / initial insomnia
- Dry mouth
- Headache
- Increased heart rate (mild; ~4–6 BPM increase in BED trials)
- Minor blood pressure increases (~1–2 mmHg systolic/diastolic)
- Irritability
- Nausea

**Duration data from clinical studies [Ref 29, Ref 35]:**
- Tmax of d-amphetamine: 3.0–4.7 hours post-dose
- Therapeutic duration: ≥13 h (children), ≥14 h (adults)
- The seed data duration values (onset 60-90 min, come-up 30-60 min, peak 3-5 h, offset 4-6 h, total 10-14 h) are broadly consistent with published PK/PD data, though the published therapeutic duration of 13-14 h suggests the total duration window may extend to the upper end of the 10-14 h range.

---

## Safety & Toxicity

### Acute Toxicity

No published LD50 data for LDX in humans were identified. Toxicity data in the context of ADHD drug overdose (which encompasses LDX as an amphetamine prodrug) describes the following spectrum of amphetamine toxidrome (Spiller et al. 2013 [Ref 23]):
- Mild: agitation, tachycardia, hypertension, tremor
- Moderate: hyperthermia, diaphoresis, vomiting, mydriasis
- Severe: seizures, rhabdomyolysis, hyperthermia (>41°C), cardiovascular collapse

The prodrug design does not eliminate toxicity once d-amphetamine is liberated; large oral doses or co-ingestion with other serotonergic drugs can produce life-threatening amphetamine toxidrome.

### Chronic Toxicity

**Growth effects:** Long-term stimulant use in children is associated with modest height and weight suppression. The 2-year Phase IV European study (Coghill et al. 2017 [Ref 28]) monitored these parameters; growth should be monitored in pediatric patients on long-term LDX.

**Cardiovascular:** Modest, generally well-tolerated increases in HR and BP are observed in clinical trials [Ref 9, Ref 37]. The BED pivotal trials found mean HR increases of 4.41–6.31 BPM and systolic BP increases of 0.2–1.45 mmHg. Contraindicated in patients with structural cardiac abnormalities, cardiomyopathy, or serious heart rhythm disorders [Ref 35].

**Psychiatric risks:** Stimulants can unmask or exacerbate tics, pre-existing psychosis, bipolar disorder, and anxiety. New-onset psychotic symptoms have been reported with therapeutic doses of amphetamines. Contraindicated in patients with agitated states or a history of drug abuse when prescribed for non-addiction purposes [Ref 35].

**Toxicity characterisation note:** Seed data toxicity rating (acute: moderate; chronic: moderate) is noted as "inferred from pharmacological class — not sourced from literature." This assessment is broadly consistent with the published evidence profile for therapeutic dose LDX in clinical populations.

---

## Harm Reduction

### Contraindications (published/regulatory)

From FDA prescribing information [Ref 35] and clinical reviews [Ref 33]:
- **MAOI co-administration or recent use (within 14 days):** absolute contraindication; risk of hypertensive crisis and serotonergic toxicity
- **Hypersensitivity to amphetamine products**
- **Structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia**
- **Moderate-to-severe hypertension**
- **Hyperthyroidism**
- **Glaucoma**
- **Agitated states**
- **History of drug abuse** (relative contraindication in non-addiction clinical contexts)

### Harm Reduction Guidance

- Avoid combining with MAOIs, tramadol, serotonergic agents, or other stimulants
- Monitor heart rate and blood pressure, especially at higher doses
- Ensure adequate hydration; appetite suppression and dry mouth increase dehydration risk
- The prodrug formulation reduces but does not eliminate the abuse-deterrent effect — oral misuse at high doses can produce significant amphetamine effects
- Drug holidays or planned breaks can help manage tolerance and assess for ongoing therapeutic necessity
- Screen for personal/family history of psychosis, bipolar disorder, or cardiac abnormalities before initiating

### Testing and Identification

LDX is detectable on standard amphetamine immunoassay drug screens and appears as d-amphetamine on confirmatory GC-MS/LC-MS testing (since the prodrug is rapidly converted before urine collection). LDX itself may not be consistently detected; the d-amphetamine metabolite will be the positive finding.

---

## Tolerance & Dependence

### Tolerance

Clinical tolerance to the cardiovascular effects (HR, BP) of stimulants is well documented and is considered a safety feature; tolerance to therapeutic (cognitive/ADHD) effects is less well established. The seed data tolerance fields are blank — no specific LDX tolerance data were identified in the literature from this search.

Amphetamine class effects (preclinical data from rodents, Riffee & Gerald 1977 [Ref in history section], and clinical observation) indicate that tolerance develops to the locomotor/euphorigenic effects with repeated use, while therapeutic efficacy in ADHD is often maintained long-term [Ref 28].

### Dependence and Withdrawal

LDX is a Schedule II substance with recognised abuse potential, though its prodrug design substantially reduces the rate of euphoria onset that drives addictive behavior [Ref 6, Ref 22]. The Jasinski & Krishnan IV study [Ref 6] is the key primary evidence for reduced abuse liability relative to immediate-release d-amphetamine.

**Withdrawal:** Stimulant (amphetamine) withdrawal is characterised by: dysphoria, fatigue, hypersomnia, increased appetite, and depressed mood — often described as a "crash." These symptoms reflect the acute depletion of monoamine stores following chronic elevated synaptic DA/NE activity. Withdrawal is not considered life-threatening but can be subjectively distressing [Ref 8].

A case report by Krakowski & Ickowicz (2018 [Ref 45]) describes stimulant withdrawal phenomena in a child with ASD/ADHD, with rebound hyperactivity and emotional dysregulation upon discontinuation.

**BED relapse following discontinuation:** A randomized 26-week withdrawal phase within a Phase 3 LDX trial for BED showed that discontinuation of LDX markedly increased risk of BED relapse relative to continued treatment [Ref 18].

**Dependence liability:** No published human case series of LDX-specific physical dependence were identified. Dependence in therapeutic populations treated for ADHD or BED at clinical doses appears rare based on trial safety data.

---

## Interactions

### MAOIs (Monoamine Oxidase Inhibitors)
**Severity: Contraindicated / Dangerous**
MAOI + amphetamine combination is an absolute contraindication. MAOIs block the metabolism of monoamines by MAO enzymes, and co-administration with amphetamines (which massively increase synaptic DA, NE, and 5-HT) causes potentially fatal accumulation of catecholamines, producing hypertensive crisis (severe hypertension, hyperthermia, headache, cardiovascular collapse). A case report by Barnett et al. (2025 [Ref 38]) describes a hypertensive emergency with ST-elevation MI from combined MAOI + extended-release dextroamphetamine-amphetamine + psilocybin mushrooms. Wait at least 14 days after MAOI discontinuation before initiating LDX [Ref 35].

### Tramadol
**Severity: Potentially dangerous / Serotonin syndrome risk (seed data flags as "lethal")**
Tramadol is a weak serotonin-norepinephrine reuptake inhibitor (SNRI) as well as a mu-opioid agonist. d-Amphetamine (the active metabolite of LDX) releases serotonin, norepinephrine, and dopamine. Combining tramadol with amphetamines creates additive serotonergic load that can precipitate serotonin syndrome — characterised by agitation, hyperthermia, muscle rigidity, clonus, autonomic instability, and potentially death [Ref 43]. Tramadol also lowers the seizure threshold, and amphetamine-induced hypertension/hyperthermia may worsen seizure risk. The seed data classification of this interaction as "lethal" is consistent with the severe end of the serotonin syndrome spectrum, though published case reports specifically documenting LDX + tramadol fatalities were not identified. The interaction should be treated as dangerous and the combination avoided.

**[FLAG FOR HUMAN REVIEW]:** The "lethal" classification in the seed data for LDX + tramadol is not supported by a specific published case report for this exact combination, but is consistent with known serotonin syndrome risk from combining serotonin-releasing agents with SNRI-activity drugs. This classification likely represents class-level inference. Editorial review of the severity tier is recommended.

### PCP (Phencyclidine)
**Severity: Dangerous (seed data)**
PCP is an NMDA antagonist and potent norepinephrine/dopamine reuptake inhibitor. Combining with a strong catecholamine releaser like d-amphetamine is expected to produce severe sympathomimetic toxicity, hyperthermia, agitation, and possible cardiovascular crisis. No specific published LDX + PCP interaction studies were identified; this is a class-based inference.

**[FLAG FOR HUMAN REVIEW]:** The "dangerous" classification for PCP + LDX is based on pharmacological class inference. No specific published interaction data were identified.

### Alcohol
**Severity: Unknown (seed data)**
No specific published data on LDX + alcohol interaction were found. Amphetamines mask the subjective sedation of alcohol (the "speedball" effect), potentially leading to alcohol overconsumption. This is a documented phenomenon with stimulants generally. The interaction mechanism does not produce direct pharmacokinetic interaction but behavioural/risk augmentation is relevant.

### Cannabis
**Severity: Unknown (seed data)**
No specific published LDX + cannabis interaction data were identified.

### GHB / GBL
**Severity: Unknown (seed data)**
No specific published LDX + GHB/GBL interaction data were identified.

### Urinary pH modifiers
**Mechanism-based interaction:** Alkalinizing agents (sodium bicarbonate, antacids) increase amphetamine reabsorption, prolonging and intensifying effects. Acidifying agents (ascorbic acid, ammonium chloride) accelerate amphetamine excretion, reducing duration and effects [Ref 35].

### Other stimulants (cocaine, caffeine)
Additive cardiovascular stress (increased HR, BP). Combination not recommended due to risk of tachyarrhythmia and hypertensive crisis.

---

## Legal Status

| Jurisdiction | Classification | Brand Name | Notes |
|---|---|---|---|
| United States | DEA Schedule II (CII) | Vyvanse® | Highest control level for medical drugs; prescription required. Generic approved 2023. |
| United Kingdom | Class B, Schedule 2 | Elvanse® | Controlled drug; equivalent to US Schedule II |
| Australia | Schedule 8 (Controlled Drug) | Vyvanse® | Highest controlled drug tier for medical substances |
| Canada | Schedule I (CDSA) | Vyvanse® | Controlled; available by prescription |
| European Union | Varies by country | Elvanse® / Tyvense® | Approved in Germany, Spain, Denmark, Sweden, Norway, Finland, Ireland (Tyvense); prescription-only |
| Japan | Designated as raw material for stimulants | Vyvanse® | Strict distribution controls; approved March 2019 for pediatric ADHD |

Sources: [Ref 19, Ref 20, Ref 21]

---

## Clinical Trials

### Completed — ADHD

| NCT ID | Title | Phase | Status | Result Summary |
|---|---|---|---|---|
| NCT00334880 | LDX in Adults with ADHD (NRP104) | Phase 3 | Completed | Positive; supported adult ADHD approval [Ref 27] |
| — | Pivotal pediatric ADHD Phase 3 (NRP-104) | Phase 3 | Completed | Positive; Biederman 2007 [Ref 15] |
| NCT01552902 | LDX vs Concerta in Adolescent ADHD | Phase 4 | Completed | Head-to-head vs extended-release MPH |
| NCT01924429 | fMRI of brain activation, adult ADHD | Phase 4 | Completed | Neuroimaging effects |

### Completed — Binge Eating Disorder

| NCT ID | Title | Phase | Status | Result Summary |
|---|---|---|---|---|
| NCT01718509 | LDX in Adults with BED | Phase 3 | Completed | Positive; McElroy 2015 [Ref 9]; supported FDA BED approval |
| Second pivotal BED trial | LDX in Adults with BED (study 2) | Phase 3 | Completed | Positive; McElroy 2015 [Ref 9] |

### Completed — MDD Augmentation (not approved)

| NCT ID | Title | Phase | Status | Result Summary |
|---|---|---|---|---|
| NCT00905424 | LDX as augmentation in MDD (SPD489) | Phase 2 | Completed | Richards 2017; dose-ranging positive |
| Two Phase 3 MDD augmentation trials | LDX augmentation in MDD | Phase 3 | Completed | Richards 2016 [Ref 41]; mixed results, not approved |

### Active / Recruiting

| NCT ID | Title | Phase | Status | Notes |
|---|---|---|---|---|
| NCT06788587 | LDX for Methamphetamine Use Disorder | Phase 2 | Recruiting | Agonist replacement therapy approach [Ref 26] |
| NCT03333668 | fMRI of Guanfacine and LDX in ADHD Adolescents | NA | Unknown | Neuroimaging combination study |

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Data Gaps

1. **SMILES and molecular formula absent from seed data** — now populated from PubChem CID 11597698 and web sources. ✅ Resolved.

2. **No published binding affinity (Ki/EC50) data specifically for LDX** — LDX is pharmacologically inert; binding data are for d-amphetamine, and its mechanism is substrate-based release rather than simple receptor binding. The generation agent should note this explicitly.

3. **No published LD50 data for LDX in humans** — toxicity characterisation is based on clinical trial AE data and amphetamine class-level toxicology (Spiller 2013 [Ref 23]).

4. **Tolerance fields blank in seed data** — no published LDX-specific tolerance development rate studies were identified. This should be noted as a gap in the article.

5. **Dependence fields blank in seed data** — no published LDX-specific physical dependence case series at therapeutic doses. The evidence is limited to withdrawal phenomena from discontinuation in BED/ADHD trials [Ref 18].

6. **Serotonin releasing activity of d-amphetamine** — seed pharmacological class includes "Serotonin releasing agent." This is accurate at high doses/concentrations but d-amphetamine is far weaker as a 5-HT releaser than as DA/NE releaser. The generation agent should note the relative potency hierarchy (DA >> NE >> 5-HT).

7. **Detailed PK parameters at each dose level** — the published PK data summarised here covers the range across doses; individual dose-level PK tables are in the FDA label and Ermer 2016 [Ref 29] but were not fully extracted.

8. **Duration data discrepancy:** Seed data total duration is 10-14 h. Published data confirms ≥13 h in children and ≥14 h in adults [Ref 29]. The lower end of the seed range (10 h) may be an underestimate for standard clinical doses; generation agent should use the literature-derived values.

### Safety-Critical Flags

**[FLAG 1 — Tramadol interaction severity]:** Seed data classifies LDX + tramadol as "lethal." Published evidence confirms serotonin syndrome risk from combining serotonin-releasing agents with tramadol's SNRI activity, with fatal cases in the broader serotonin syndrome literature. However, no published case report specifically documenting a LDX + tramadol fatality was found. This classification likely reflects class-level inference and may represent conservative (protective) over-classification. Recommend flagging for medical editorial review before finalising.

**[FLAG 2 — PCP interaction severity]:** Seed data classifies LDX + PCP as "dangerous." No specific published interaction studies identified. Classification appears to be pharmacological class inference. Requires editorial review.

**[FLAG 3 — Serotonin releasing agent classification]:** Seed data lists "Serotonin releasing agent" in pharmacological class. While technically accurate, this requires careful framing — d-amphetamine's serotonergic activity is substantially weaker than its dopaminergic/noradrenergic activity, and the serotonin syndrome risk arises primarily from pharmacokinetic/pharmacodynamic interactions with other serotonergic agents rather than from LDX alone at therapeutic doses.

**[FLAG 4 — Characterisation as "emerging"]:** Seed data characterises LDX as "emerging." This is incorrect — LDX has been FDA-approved since 2007, has extensive published Phase 3 data, and is among the most widely prescribed stimulants globally. The characterisation should be updated to "well-established" or equivalent.

**[FLAG 5 — Dose data]:** Seed data dose range appears clinically reasonable (30-70 mg is the approved therapeutic range). However, the published trial evidence confirms significant therapeutic effect at 30, 50, and 70 mg. The "threshold" at 10 mg and "heavy" at 90+ mg are not derived from controlled human studies but represent plausible pharmacological extrapolations based on d-amphetamine dose-effect curves. Generation agent should note that doses >70 mg are not supported by clinical trial evidence and carry elevated cardiovascular risk.